Navigation Links
Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Date:3/14/2012

ANN ARBOR, Mich., March 14, 2012 /PRNewswire/ -- Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta™) for the treatment of relapsing-remitting multiple sclerosis (MS). With over $8 million in external grant funding awarded to date, this Trimesta clinical trial should be fully funded to its completion.

"The completion of patient enrollment into the Phase II Trimesta trial represents another important milestone for oral estriol and brings us one step closer to offering a new oral treatment option to patients with relapsing-remitting MS," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "As an oral therapy with a promising clinical profile, Trimesta is expected to be extremely well positioned to provide an important treatment option for this debilitating disease."

The randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of Trimesta (oral estriol) for relapsing-remitting MS in women initially enrolled a total of 164 patients. At 15 sites in the United States, clinical investigators have been administering either oral Trimesta or matching placebo in addition to glatiramer acetate (Copaxone®), an FDA-approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. MS patients are being dosed and monitored for two years. The primary outcome measure for the study is the rate of relapse between the placebo and treated groups at two years, an accepted FDA-approvable endpoint in MS.  Additional information regarding the relapsing-remitting MS clinical trial
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
2. Adeona Becomes Synthetic Biologics, Inc.
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
6. Synthetic Biology: Emerging Global Markets
7. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
8. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
9. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
10. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... today published analyses of its second-generation map of ... markers than the initial version unveiled in 2005. ... consortium describes how the higher resolution map offers ... common diseases, explore the structure of human genetic ...
... FRANCISCO, Calif., Oct. 17 Monogram,Biosciences, Inc., (Nasdaq: ... on Wednesday, October 24, 2007 at 4:30 p.m. (Eastern ... will be hosted by Mr.,William D. Young, Chairman and ... teleconference, please call (877) 548-7912,or (719) 325-4878 for international ...
... ARNA ) today reported financial results for the ... the third quarter of 2007 were $5.0 million, compared,to ... revenues in the first,nine months of 2007 were $14.8 ... of 2006. Revenues in the first nine months of ...
Cached Biology Technology:Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Robert Burns compared his love to a red, red rose, ... rather than being topped by a lovely, fragrant bloom, a ... crowned by a homely second root. , Researchers at the ... plant Arabidopsis thaliana rather than the elegant rose recently determined ...
... University at Buffalo have received a $2.5 million five-year ... dysfunction called "hibernating myocardium" that can cause disabling heart ... a condition in which myocytes (cells in the heart's ... that receive reduced blood flow over an extended period ...
... University of Florida scientists conducting experiments with mice have ... of cells in the eye essential for healthy vision. ... cell layer vital for eyesight called the retinal pigment ... writing in a recent issue of Investigative Ophthalmology & ...
Cached Biology News:Salk scientists get to the root of plant cell fate 2Salk scientists get to the root of plant cell fate 3Reversing 'hibernating' heart muscle focus of UB researchers 2Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: